Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Robert I. Haddad et al.|Annals of Oncology|2020Cited by 365
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, L. Rouxel et al.|Annals of the Rheumatic Diseases|2017Cited by 302
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I. Haddad, Athanassios Argiris, Kevin J. Harrington et al.|Journal of Clinical Oncology|2022Cited by 159
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Alice Tison et al.|European Journal of Cancer|2021Cited by 93
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).Lisa Licitra, Robert L. Ferris, Robert I. Haddad et al.|Journal of Clinical Oncology|2019Cited by 39